ALX Oncology lists Jeff Knight as reporting insider

ALX Oncology Holdings Inc identified Jeff E. Knight, its Chief Dev & Operating Officer, as a reporting person in a Form 3 insider filing.

Accepted by SEC EDGAR 04/17/2026 - 04:10 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ALX Oncology Holdings Inc identified Jeff E. Knight, its Chief Dev & Operating Officer, as a reporting person in a Form 3 insider filing. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, and no holdings are detailed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the reporting person in ALXO's Form 3 filing?

The reporting person is Jeff E. Knight, listed as Chief Dev & Operating Officer of ALX Oncology Holdings Inc. He is the only reporting person shown in the data, with officer status indicated and no director or ten-percent-owner designation.

Does the ALXO Form 3 for Jeff Knight show any insider trades?

No trades are shown. The transaction summary lists zero buys, zero sells, zero acquisitions, and zero dispositions, indicating that no purchases or sales are reported in this Form 3 data excerpt for Jeff E. Knight.

Are any derivative securities reported for Jeff Knight in ALXO's Form 3?

No derivative positions are reported in the provided data. The derivativeSummary is empty and the transaction summary shows zero derivative transactions and zero option or similar exercises, indicating no derivatives are listed here.

Does the ALXO Form 3 indicate any gifts or tax withholding transactions?

No. The transaction summary shows giftCount and taxWithholdingCount both at zero, and giftShares and taxWithholdingShares at zero, meaning no gifts or tax-withholding dispositions are reflected in this Form 3 excerpt.

What does the transactionSummary in ALXO's Form 3 indicate overall?

The transactionSummary shows zero activity across all categories, including buys, sells, exercises, gifts, tax withholdings, and restructurings. It also notes a netBuySellDirection of neutral, consistent with no reported transactions in this dataset.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Knight Jeff E.

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/13/2026

3. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Dev & Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Shelly Wong, by power of attorney	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)